Diane Anastasiou
Diane Anastasiou has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Stephen Villano
Paratek Pharmaceuticals, Inc. , king of Prussia, Pennsylvania
2 shared publications- Alisa W. Serio
Paratek Pharmaceuticals, Inc., King of Prussia, Pennsylvania, USA
1 shared publication Alissa Sirbu
Paratek Pharmaceuticals, Inc. , king of Prussia, Pennsylvania
1 shared publicationAmy Manley
Paratek Pharmaceuticals, Inc. , king of Prussia, Pennsylvania
1 shared publication- Amy Manley
Paratek Pharmaceuticals, Inc., King of Prussia, USA
1 shared publication Anita F Das
AD Stats Consulting , Guerneville, California
1 shared publication
Latest Publications
- Open Access
- 3 March 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , e133-e142
Omadacycline Monotherapy in Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus : Results From a Phase 2, Double-blind, Randomized, Placebo-controlled Study
Omadacycline is an FDA-approved oral and intravenous treatment for adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection that demonstrates potent in vitro activity and in vivo efficacy versus Mycobacterium abscessus. A randomized, double-blind, placebo-controlled, multicenter phase 2 study of omadacycline monotherapy was conducted in adults with nontuberculous mycobacterial pulmonary disease (NTM-PD) caused by M. abscessus. Eligible patients meeting the diagnostic criteria for NTM-PD were randomized 1.5:1 to receive omadacycline 300 mg orally once daily or placebo for 84 days. Randomization was stratified by prior antibiotic treatment for M. abscessus (yes/no). Sixty-six patients were randomized (41 omadacycline, 25 placebo). At baseline, cough, fatigue, mucus production, shortness of breath, and throat clearing were the most bothersome and common symptoms (68.2%–95.4% of patients). For the primary endpoint, 34.1% and 20.0% of omadacycline and placebo patients, respectively, were responders by definition 1 (improvement in symptom severity at day 84 for at least half of baseline symptoms) and 34.1% and 12.0%, respectively, were responders by definition 2 (definition 1 plus no deterioration in severity of any baseline symptom). Key secondary and exploratory clinical and microbiological endpoints also favored omadacycline compared with placebo. Four (9.8%) patients discontinued omadacycline therapy due to a treatment-emergent adverse event (TEAE). The most frequent omadacycline-related TEAEs were gastrointestinal, particularly nausea. Results consistently favored omadacycline monotherapy over placebo across several endpoints in NTM-PD caused by M. abscessus. Omadacycline was well tolerated; nausea was the most frequent TEAE. Further investigations are warranted.
- 3 March 2026
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 83 (1) , e133-e142
Open AccessOmadacycline Monotherapy in Nontuberculous Mycobacterial Pulmonary Disease Caused by Mycobacterium abscessus : Results From a Phase 2, Double-blind, Randomized, Placebo-controlled Study
Omadacycline is an FDA-approved oral and intravenous treatment for adults with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infection that demonstrates potent in vitro activity and in vivo efficacy versus Mycobacterium abscessus. A randomized, double-blind, placebo-controlled, multicenter phase 2 study of omadacycline monotherapy was conducted in adults with nontuberculous mycobacterial pulmonary disease (NTM-PD) caused by M. abscessus. Eligible patients meeting the diagnostic criteria for NTM-PD were randomized 1.5:1 to receive omadacycline 300 mg orally once daily or placebo for 84 days. Randomization was stratified by prior antibiotic treatment for M. abscessus (yes/no). Sixty-six patients were randomized (41 omadacycline, 25 placebo). At baseline, cough, fatigue, mucus production, shortness of breath, and throat clearing were the most bothersome and common symptoms (68.2%–95.4% of patients). For the primary endpoint, 34.1% and 20.0% of omadacycline and placebo patients, respectively, were responders by definition 1 (improvement in symptom severity at day 84 for at least half of baseline symptoms) and 34.1% and 12.0%, respectively, were responders by definition 2 (definition 1 plus no deterioration in severity of any baseline symptom). Key secondary and exploratory clinical and microbiological endpoints also favored omadacycline compared with placebo. Four (9.8%) patients discontinued omadacycline therapy due to a treatment-emergent adverse event (TEAE). The most frequent omadacycline-related TEAEs were gastrointestinal, particularly nausea. Results consistently favored omadacycline monotherapy over placebo across several endpoints in NTM-PD caused by M. abscessus. Omadacycline was well tolerated; nausea was the most frequent TEAE. Further investigations are warranted.
- Open Access
- 21 November 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 90
Omadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial
- 21 November 2025
- Published by Elsevier in eClinicalMedicine
- Vol. 90
Open AccessOmadacycline versus moxifloxacin for community-acquired bacterial pneumonia (OPTIC-2): a phase 3b, randomised, double-blind, multicentre, controlled, noninferiority trial